Etomoxir |
| Catalog No.GC16736 |
Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a). Etomoxir inhibits fatty acid oxidation (FAO) and palmitate oxidation via CPT-1a.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 124083-20-1
Sample solution is provided at 25 µL, 10mM.
Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a). Etomoxir inhibits fatty acid oxidation (FAO) and palmitate oxidation via CPT-1a[1].
T cells cultured in a low-glucose medium in the presence of Etomoxir (100μM) significantly reduce interferon-gamma (IFN-γ) production and do not promote T-helper 2 (Th2)-related cytokine IL-4 production, while Etomoxir does not affect T cells cultured in the high-glucose medium[2]. Etomoxir (500μM) can significantly inhibit FAO in A549 and A549T cells. Etomoxir at 500μM or 1mM can significantly increase the sensitivity of paclitaxel-resistant cells (A549T) to paclitaxel[3].
In experimental autoimmune encephalomyelitis (EAE) mice, Etomoxir (15mg/kg) reduces inflammatory responses, immune cell infiltration in the central nervous system (CNS), as well as inflammation and demyelination in the CNS[2]. In C57BLKS/J lar-Leprdb/db and high-fat (HF)-fed mice, Etomoxir (1mg/kg) significantly reduces the decrease in bone mineral density (BMD) and bone-breaking strength and inhibits the decrease in osteoblasts differentiated from bone marrow stromal cells (BMSCs)[4].
References:
[1] Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36.
[2] Shriver L P, Manchester M. Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis[J]. Scientific Reports, 2011, 1(1): 79.
[3] Li J, Zhao S, Zhou X, et al. Inhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitizes drug-resistant lung adenocarcinoma cells to paclitaxel[J]. PloS one, 2013, 8(9): e74623.
[4] Li J, He W, Liao B, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to the reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus[J]. Scientific Reports, 2015, 5(1): 12724.
| Cell experiment [1]: | |
|
Cell lines |
Rat heart H9c2 myoblastic cells |
|
Preparation Method |
H9c2 cells were preincubated with 1–80μM Etomoxir for 2h and incubated with 0.1mM [1-14C]oleic acid bound to albumin for 2h, and radioactivity incorporated into cardiolipin (CL) determined. |
|
Reaction Conditions |
1-80μM; 2h |
|
Applications |
In rat cardiac H9c2 myoblasts, Etomoxir reduced [1-14C]oleic acid incorporation into phosphatidylglycerol (PtdGro) and cardiolipin (CL) in a concentration-dependent manner and increased [1,3-3H]glycerol incorporation into CL. |
| Animal experiment [2]: | |
|
Animal models |
Experimental autoimmune encephalomyelitis (EAE) mice model |
|
Preparation Method |
EAE was induced with a peptide from myelin oligodendrocyte glycoprotein (MOG35–55) and mice were administered Etomoxir. |
|
Dosage form |
15mg/kg, On days 8 and 15 after EAE induction, i.p. |
|
Applications |
Etomoxir treatment reduced inflammatory responses and immune cell infiltration in the central nervous system of EAE mice. |
|
References: |
|
| Cas No. | 124083-20-1 | SDF | |
| Chemical Name | ethyl (2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate | ||
| Canonical SMILES | CCOC(=O)C1(CO1)CCCCCCOC2=CC=C(C=C2)Cl | ||
| Formula | C17H23ClO4 | M.Wt | 326.82 |
| Solubility | ≥ 32.7 mg/mL in DMSO, ≥ 109.6 mg/mL in EtOH, ≥ 48.3 mg/mL in Water with gentle warming | Storage | Store at -20°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0598 mL | 15.2989 mL | 30.5979 mL |
| 5 mM | 0.612 mL | 3.0598 mL | 6.1196 mL |
| 10 mM | 0.306 mL | 1.5299 mL | 3.0598 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Characterization of PCL/PTX@DSPE/ET. (H and I) PTX (H) and etomoxir (I) release profiles of PCL/PTX@DSPE/ET and PCL/PTX-DSPE/ET in PBS, pH 7.4.
Etomoxir (ET) was purchased from GlpBio (Montclair, USA).
Nanoscale 15.18 (2023): 8320-8336. PMID: 37083874 IF: 6.7 -
Related Biological Data
Sodium butyrate significantly inhibited lipogenic genes and activated lipid oxidation-related gene expression in the primary hepatocytes. L) Palmitate (PA) -OCR assay in the presence of sodium butyrate.
Hep1-6 were then treated sequentially with BSA-conjugated palmitate (200 μM), oligomycin (Oligo) (2 μM), fluorocarbonyl cyanide phenylhydrazone (FCCP) (2.5 μM), and etomoxir (Eto) (GLPBIO) (50 μM) as indicated.
Mol Nutr Food Res (2022): 2200597. PMID: 36382553 IF: 6.5749 -
Related Biological Data
(H) Western blot results of apoptosis-related proteins after 72 h of treatments of inhibitors only or combined with paclitaxel.
A2780/Taxol cells were pretreated separately using etomoxir (GLPBIO) and CAY10566 with or without paclitaxel for 48 h.
Int J Mol Sci 24.22 (2023): 16503. PMID: 38003694 IF: 5.5999
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *